Direct Comparison of Inositol Phosphoglycan with Prostaglandylinositol Cyclic Phosphate, Two Potential Mediators of Insulin Action

Abstract

Though insulin signalling is thought by many groups to function without second messenger action, others have provided evidence for the existence and action of such regulators. Chemically quite different compounds, however, have been proposed as mediators, such as various inositol phosphoglycans and prostaglandylinositol cyclic phosphate (cyclic PIP). In spite of marked structural differences, these compounds are reported to have the same regulatory properties, i.e. to activate protein ser/thr phosphatases and to inhibit protein kinase A. In order to clarify this discrepancy, the regulatory potency of these different compounds was assayed under identical conditions. It was found that in contrast to cyclic PIP, the synthetic inositol phosphoglycan PIG41 neither directly inhibited protein kinase A nor activated protein ser/thr phosphatases. However, when added to intact cells, such as primary adipocytes, PIG41 inhibited isoproterenol-stimulated lipolysis. This effect most likely results from tyrosine phosphorylation of insulin receptor substrates (IRSs) by PIG41. This tyrosine phosphorylation is not carried out by the insulin receptor tyrosine kinase but by cytosolic tyrosine kinases. This indicates that cyclic PIP, an intracellular regulator, which primarily acts on protein kinase A and on protein ser/thr phosphatases, operates more downstream in the signal transduction cascade as compared to the inositol phosphoglycan PIG41. Thus, cyclic PIP appears to be a suitable candidate to close the gap between IRSs and the protein kinases/phosphatases involved in the signal transduction of insulin.

Inositol phosphoglycan - insulin action - prostaglandylinositol cyclic phosphate - protein kinase A - protein phosphatases - signal transduction

References

• 1 Beavo J A, Bechtel P J, Krebs E G. Preparation of homogeneous cyclic AMP-dependent protein kinase(s) and its subunits from rabbit skeletal muscle.  Methods Enzymol. 1974;  38 299-308
• 2 Brodbeck U. Signalling properties of glycosylphosphatidylinositols and their regulated release from membranes in the turnover of glycosylphosphatidylinositol-anchored proteins.  Biol Chem. 1998;  379 1041-1044
• 3 Cohen P. The structure and regulation of protein phosphatases.  Annu Rev Biochem. 1989;  58 453-508
• 4 Eggstein M, Kuhlmann E. Triglyceride und Glycerin. Bergmeier HU Methoden der enzymatischen Analyse. 3rd ed. Weinheim, Bergstraße; Verlag Chemie 1974: 1871-1877
• 5 Frick W, Bauer A, Bauer J, Wied S, Müller G. Insulin-mimetic signalling of synthetic phosphoinositolglycans in isolated rat adipocytes.  Biochem J. 1998 a;  336 163-181
• 6 Frick W, Bauer A, Bauer J, Wied S, Müller G. Structure-activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action.  Biochemistry. 1998 b;  37 13421-13436
• 7 Giorgione J R, Turco S J, Epand R M. Transbilayer inhibition of protein kinase C by the lipophosphoglycan from Leishmania donovani.  Proc Natl Acad Sci USA. 1996;  93 11634-11639
• 8 Gypakis A, Wasner H K. Biosynthesis of activated inositol phosphate, a novel class of inositol phosphates (abstract).  Exp Clin Endocr Diab. 1996;  104 A18
• 9 Gypakis A, Wasner H K. Phosphatidylinositol 3-kinase and prostaglandylinositol cyclic phosphate (cyclic PIP), a mediator of insulin action, in the signal transduction of insulin.  Biol Chem. 2000;  381 1139-1141
• 10 Jones D R, Varela-Nieto I. Diabetes and the role of inositol-containing lipids in insulin signaling.  Mol Med. 1999;  5 505-514
• 11 Kahn C R. Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes.  Diabetes. 1994;  43 1066-1084
• 12 Kessler A, Müller G, Wied S, Crecelius A, Eckel J. Signalling pathways of an insulin-mimetic phosphoinositolglycan-peptide in muscle and adipose tissue.  Biochem J. 1998;  330 277-286
• 13 Larner J, Huang L C. Identification of a novel inositol glycan signaling pathway with significant therapeutic relevance to insulin resistance: an insulin signaling model using both tyrosine kinase and G-proteins.  Diabetes Reviews. 1999;  7 217-231
• 14 Martin-Lomas M, Khiar N, Garcia S, Koessler J-L, Nieto P M, Rademacher T W. Inositolphosphoglycan mediators structurally related to glycosyl phosphatidylinositol anchors: Synthesis, structure and biological activity.  Chem Eur J. 2000;  6 3608-3621
• 15 Miller T B. Insulin regulation of glycogen synthase in rat heart and liver. Czech MP Molecular Basis of Insulin Action. New York; Plenum Press 1985: 247-261
• 16 Müller G, Schubert K, Fiedler F, Bandlow W. The cAMP-binding ectoprotein from Saccharomyces cerevisiae is membrane-anchored by glycosylphosphatidylinositol.  J Biol Chem. 1992;  267 25337-25346
• 17 Müller G, Wied S, Crecelius A, Kessler A, Eckel J. Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms.  Endocrinology. 1997;  138 3459-3475
• 18 Müller G, Wied S, Piossek C, Bauer A, Bauer J, Frick W. Convergence and divergence of the signaling pathways for insulin and phosphoinositolglycans.  Mol Med. 1998;  4 299-323
• 19 Müller G, Wied S, Frick W. Cross talk of pp125^FAK and pp59^Lyn non-receptor tyrosine kinases to insulin-mimetic signaling in adipoctes.  Mol Cell Biol. 2000;  20 4708-4723
• 20 Reiman E M, Walsh D A, Krebs E G. Purification and properties of rabbit skeletal muscle adenosine 3′, 5′-monophosphate-dependent protein kinase.  J Biol Chem. 1971;  246 1986-1995
• 21 Romero G, Gómez G, Huang L C, Lilley K, Luttrell L. Anti-inositolglycan antibodies selectively block some of the actions of insulin in intact BC₃H1 cells.  Proc Natl Acad Sci USA. 1990;  87 1476-1480
• 22 Shashkin P N, Wasner H K, Ortmeyer H K, Hansen B C. Prostaglandylinositol cyclic phosphate (cPIP): a novel second messenger of insulin action. Comparative analysis of two kinds of “insulin mediators”.  Diabetes Metab Res Rev. 2001;  17 273-284
• 23 Soderling T R, Park C R. Recent advances in glycogen metabolism.  Advances Cyclic Nucleotide Res. 1974;  4 283-333
• 24 Tachado S D, Gerold P, Schwarz R, Novakovic S, McConville M, Schofield L. Signal transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, Trypanosoma, and Leishmania: Activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol moieties.  Proc Natl Acad Sci USA. 1997;  94 4022-4027
• 25 Tiede A, Bastisch I, Schubert J, Orlean P, Schmidt R E. Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes.  Biol Chem. 1999;  380 503-523
• 26 Varela-Nieto I, León Y, Caro H N. Cell signalling by inositol phosphoglycans from different species.  Comp Biochem Physiol. 1996;  115 B 223-241
• 27 Villalba M, Kelly K L, Mato J M. Inhibition of cyclic AMP-dependent protein kinase by the polar head group of an insulin-sensitive glycophospholipid.  Biochim Biophys Acta. 1988;  968 69-76
• 28 Wasner H K. Regulation of protein kinase and phosphoprotein phosphatase by cyclic AMP and cyclic AMP antagonist.  FEBS Lett. 1975;  57 60-63
• 29 Wasner H K. Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenalin- or insulin-stimulation (isolation, purification and prostaglandin E requirement for its synthesis).  FEBS Lett. 1981;  133 260-264
• 30 Wasner H K, Kaufmann R, Lemoine H. Mass spectrometric identification of prostaglandylinositol, the dephosphorylated cyclic AMP antagonist, cyclic PIP.  Analusis. 1992;  20 171-177
• 31 Wasner H K, Salge U, Gebel M. The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone-stimulated synthesis and identification as prostaglandylinositol cyclic phosphate.  Acta Diabetol. 1993;  30 220-232
• 32 Wasner H K, Leßmann M, Conrad M, Amini H, Psarakis E, Mir-Mohammad-Sadegh A. Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes.  Acta Diabetol. 1996;  33 126-138
• 33 Wasner H K, Gebel M, Hucken S, Schaefer M, Kincses M. Two different mechanisms for activation of cyclic PIP synthase: by a G protein or by protein tyrosine phosphorylation.  Biol Chem. 2000;  381 145-153
• 34 Weber T M, Joost H G, Simpson I A, Cushman S W. Methods for assessment of glucose transport activity and the number of glucose transporters in isolated rat adipose cells and membrane fractions. Kahn CR, Harrison L Receptor Biochemistry and Methodology. Insulin Receptor, Part B: Clinical Assessment, Biological Responses and Comparison to the IGF-1 Receptor. New York, USA; Alan R Liss Inc 1988: 171-187